Preeclampsia remains a major health concern, affecting 5-10% of all pregnancies in the United States. It is a leading cause of maternal and perinatal morbidity and mortality. Currently, there is no effective therapy for the management of the preeclamptic patient, with the disease only remitting after birth. While the underlying mechanisms are not clear, it is believed that inadequate remodeling of the maternal vasculature leads to placental hypo-perfusion, resulting in chronic placental hypoxia/ischemia. In response the placenta releases pathogenic factors into the maternal blood stream, leading to widespread maternal endothelial dysfunction and hypertension. In recent years, a great deal of attention has been focused on the secretion of an anti- angiogenic protein, the fms-like tyrosine kinase-1 (sFlt-1). This protein is secreted into the maternal circulation by the ischemic placenta, where it directly antagonizes VEGF, and is responsible for a significant pathology associated with preeclampsia, including hypertension. While a great deal of research has focused on the pathogenic role of the protein, the molecular mechanisms which regulate its secretion remain obscure. One potential mechanism is suggested through the presence of a heparin binding site on the sFlt-1 protein and recent evidence from the literature that the switch between local retention and systemic release of sFlt-1 during normal pregnancy can be regulated by the expression of heparanase, which cleaves extracellular heparan, presumably releasing sFlt-1 into the extracellular space. This proposal seeks to test the hypothesis that the secretion of maternal sFlt-1, and thus the maternal hypertension, by the ischemic placenta is regulated by the expression of heparanase. Further, I will investigate the molecular mechanisms which regulate hypoxia- induced heparanase expression. Finally I propose that manipulation of either heparanase activity, or manipulation of the molecules regulating heparanase expression, can attenuate the hypertension produced by placental ischemia, suggesting new therapeutic approaches for the management of preeclampsia. In order to test these hypotheses, a number of in vitro and in vivo approaches will be used.

Public Health Relevance

Preeclampsia affects ~5-20% of all pregnancies in the United States and is a leading cause of illness and death in both the mother and newborn. This project aims to study one of the factors which causes the symptoms of preeclampsia and identify ways to block its action. As there is currently no effective treatment of preeclampsia, it is hoped these studies will provide new therapeutic approaches for the management of the disease.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Career Transition Award (K99)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-P (O1))
Program Officer
Carlson, Drew E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Mississippi Medical Center
Schools of Medicine
United States
Zip Code
George, Eric M; Cockrell, Kathy; Arany, Marietta et al. (2017) Carbon Monoxide Releasing Molecules Blunt Placental Ischemia-Induced Hypertension. Am J Hypertens 30:931-937
George, Eric M; Garrett, Michael R; Granger, Joey P (2014) Placental ischemia induces changes in gene expression in chorionic tissue. Mamm Genome 25:253-61
George, Eric M; Palei, Ana C; Dent, Edward A et al. (2013) Sildenafil attenuates placental ischemia-induced hypertension. Am J Physiol Regul Integr Comp Physiol 305:R397-403